Verve Therapeutics
Yuri Matsumoto is Associate Director, Bioanalysis at Verve Therapeutics, with expertise in bioanalytical assay development for discovery, preclinical and clinical applications. Prior to joining Verve, Dr. Matsumoto worked on protein engineering of Cas9 and research assay development at Intellia Therapeutics. Prior to Intellia, Dr. Matsumoto worked on preclinical and clinical assay development of a monoclonal antibody therapy to treat diabetic macula edema at Eleven Biotherapeutics. Dr. Matsumoto received her Ph.D. in biological engineering from MIT, where she harnessed the power of directed evolution to engineer a highly magnetic ferritin mutant to serve as a genetically-encodable MRI contrast agent.
Verve Therapeutics
59 followers
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.